Metraipolis › archive › dc_6eed033982ee

Off-label applications of omalizumab: Current insights and perspectives — Europe PMC PMID:41488545

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41488545
DOI: 10.1016/j.waojou.2025.101156
License (as archived): solo-consultazione
Archived: 2026-11-07T16:41:33.315Z
SHA-256 of the archived text: 84229e3bdbc0dd27caf064793d2cc4b1d5b72a0efee1c014b980a6df06ee00f6
Stable URL of this page: https://metraipolis.com/documento/dc_6eed033982ee

How to cite

Off-label applications of omalizumab: Current insights and perspectives — Europe PMC PMID:41488545 — Europe PMC (en), https://europepmc.org/article/MED/41488545 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6eed033982ee (Metraipolis archive dc_6eed033982ee, sha256 84229e3bdbc0dd27caf064793d2cc4b1d5b72a0efee1c014b980a6df06ee00f6)

BibTeX

@misc{dc6eed033982ee,
  title = {Off-label applications of omalizumab: Current insights and perspectives — Europe PMC PMID:41488545},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41488545},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6eed033982ee; sha256 84229e3bdbc0dd27caf064793d2cc4b1d5b72a0efee1c014b980a6df06ee00f6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41488545. Agents can read the archived copy with the MCP tool read_document.